구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)) National Eye Institute (NEI)·Leber's Hereditary Optic Neuropath… 61 trials |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med) |
Overview Company | National Eye Institute (NEI) |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | target, and multi‑pathway |
MoA Biomarker | biomarker and a new molecular target for IVDD, thereby providing a foundation for future functional and mecha |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Safety signal | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Result source | ClinicalTrials.gov NCT02161380 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02161380 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Med (injection of scAAV2-P1ND4v2 5.81 X10e9 vg, injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med)) National Eye Institute (NEI)·Leber's Hereditary Optic Neuropath… 61 trials |
|---|---|
Overview Program | injection of scAAV2-P1ND4v2 5.81 X10e9 vg (Med) |
Overview Company | National Eye Institute (NEI) |
Overview Modality | CGT |
Overview Target | Leber's Hereditary Optic Neuropathy |
Overview Indication | Leber's Hereditary Optic Neuropathy |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
MoA Mechanism | target, and multi‑pathway |
MoA Biomarker | biomarker and a new molecular target for IVDD, thereby providing a foundation for future functional and mecha |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacodynamic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Safety signal | Dual prodrugs of N 4 -hydroxycytidine with ProTide and ester modifications as anti-SARS-CoV-2 agents.. Molnupiravir, an oral prodrug of β-D-N 4 -hydroxycytidine (NHC), is a broad-spectrum antiviral agent. However, its clinical efficacy is hampered by suboptimal plasma stability and inefficient intracellular monophosphorylation. To circumvent these pharmacological limitations, a novel series … |
Clinical Result source | ClinicalTrials.gov NCT02161380 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT02161380 |
추천 비교
추천 비교